Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Xiaomi Shares Jump on Europe EV Expansion Plan 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Anthropic IPO Marketing Expected to Start in Mid-October 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
NEW YORK and MELBOURNE, Australia, Feb. 26, 2018 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the first half year ended December 31, 2017 in a webcast beginning at 4:30 pm EST on Tuesday, February 27, 2018; 8:30 am Wednesday, February 28, 2018 AEDT.
The live webcast can be accessed via
http://webcasting.brrmedia.com/broadcast/5a6ffa22271b41638bdc2f22
To access the call only, dial 1 855 881 1339 (U.S.), 1 800 558 698 (toll-free Australia) or +61 2 9007 3187 (outside of the U.S. and Australia). The conference identification code is 882151.
The archived webcast will be available on the Investor page of the Company’s website – www.mesoblast.com
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, immune-mediated and inflammatory disorders, orthopedic disorders, and oncologic/hematologic conditions.
For further information, please contact:
Julie Meldrum
Corporate Communications
Mesoblast Limited
T: +61 3 9639 6036
E: [email protected]
Schond Greenway
Investor Relations
Mesoblast Limited
T: +1 212 880 2060
E: [email protected]
